Therapeutic Advances in non-small cell Lung Cancer

Corey J. Langer, MD, FACP is board-certified in internal medicine and hematology/oncology. He is a Professor of Medicine in the Hematology/Oncology Division at the University of Pennsylvania in Philadelphia, PA, where he serves as Director of Thoracic Oncology in the Abramson Cancer Center and co-leads its Translational Therapeutics Program. Dr. Langer received his medical degree from Boston University in Boston, MA in 1981 and completed his internship and residency in medicine at the Graduate Hospital of the University of Pennsylvania. Additional postgraduate training included a fellowship in hematology/oncology at the Penn Presbyterian Medical Center and a fellowship in oncology at AOH/Fox Chase Cancer Center (FCCC).

Dr. Langer served in the oncology division of FCCC for 22 years from 1986 until 2008, and for the last 14 years of his tenure there, he led its Thoracic Oncology Program. He also served as the Research Chair of Oncology Physicians Network, a consortium of academic and community facilities in the Delaware Valley allied with FCCC. In June of 2008, he moved to the University of Pennsylvania where he currently leads the Thoracic Oncology Program.

Dr. Langer is a fellow of the American College of Physicians and is a member of the American Society of Clinical Oncology (ASCO), the American Association for Cancer Research (AACR), the International Association for the Study of Lung Cancer (IASLC), and the Society of Head and Neck Surgeons. He serves as vice-chair of the Radiation Therapy Oncology Group (RTOG) and chairs its Medical Oncology Subcommittee. He also serves on the core Thoracic and Head and Neck Committees of both the Eastern Cooperative Oncology Group (ECOG) and RTOG. He is chair of the Commission on Cancer, Head and Neck Cancer Database Committee, under the aegis of the American College of Surgeons.

Also, Dr. Langer has contributed numerous articles (>140) and abstracts to medical literature. His work on head and neck squamous cell cancer and non-small cell lung cancer has appeared in the New England Journal of Medicine (NEJM), Seminars in Oncology, Clinical Cancer Research, Journal of Clinical Oncology, Journal of Thoracic Oncology, Clinical Lung Cancer, Cancer, Lung Cancer, Cancer Investigation, and EJC. His work has also been presented at the national meetings of ASCO, AACR, ASH, and the IASLC. He has served three separate terms as a member of the editorial board of the Journal of Clinical Oncology, and is currently on the editorial boards of Clinical Lung Cancer and Clinical Advances in Hematology and Oncology. He is also a frequent lecturer at numerous medical symposia and grand rounds.

Mark A. Socinski, MD is Professor of Medicine and co-leader of the Multidisciplinary Thoracic Oncology Program at the Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill. A national expert on lung cancer, he serves as co-chair of the National Cancer Institutea[euro](TM)s Thoracic Malignancy Steering Committee and is an active member of the Respiratory Committee of the Cancer and Leukemia Group B.

Dr. Socinski has led national and international trials of new therapies, most recently an international clinical trial evaluating BLP25 liposome vaccine. His clinical research findings have been published in numerous journals, including the Journal of Clinical Oncology and the Journal of Thoracic Oncology.

He earned his undergraduate degree in zoology from the University of Vermont, followed by both his medical degree and a master's degree in pathology from the University of Vermont in Burlington, VT. He completed his residency in internal medicine at Harvard Medical Schoola[euro](TM)s Beth Israel Hospital and a fellowship in medical oncology at the Dana-Farber Cancer Institute in Boston, MA.